Citations

Clear

6273 citation(s) found for "To, Andrew".

Comparison of Total Lung Capacity Determined by Plethysmography With Computed Tomographic Segmentation Using CALIPER
Matsumoto, Andrew , Bartholmai, Brian J. , Wylam, Mark E. , Matsumoto, Andrew J, Bartholmai, Brian J

Mayo Clinic

Journal of Thoracic Imaging | November 18, 2016 | Volume: 32 | Issue: 2 | Pages: 101-106

10.1097/rti.0000000000000249 | PMID 27870822 Get It

Purpose: Traditionally, determination of total lung capacity (TLC) by plethysmography (TLCpleth) has been important in the diagnosis of lung diseases. Alternatively, data acquired from computerized tomography (CT) can be utilized to calculate a measure of TLC (TLCCT). The clinical utility of TLCCT is not certain. We sought to determine, in a clinical setting, whether TLCCT correlates with TLCpleth across a range of lung diseases and scanning techniques. In addition, we determined whether TLCCT affects the interpretation of pulmonary function tests. Subjects and Methods: Records of 118 of 148 consecutive lung transplant recipients were reviewed and determined to have coinciding pulmonary function tests, including plethysmography as well as volumetric chest CT performed supine during full inspiration. CT images acquired with a wide range of scanning protocols were analyzed using CALIPER, a software program for lung and trachea extraction from a CT volume and volumetric tissue characterization of the lung. Segmentation of the lung was achieved by using completely automated dynamic thresholding and region-growing techniques developed to extract the relatively low-density lung and tracheal anatomy from the CT data set without user intervention. Results: TLCpleth and TLCCT were strongly related with a correlation coefficient of 0.88 (P<0.001). The efficacy of the CT-derived measure was not influenced by specific lung diagnoses, age, height, body mass index, or spirometric parameters. TLCCT did not misidentify any diagnosis of restrictive lung disease, nor hyperinflation. Conclusions: In a clinical setting, CT segmentation analysis provides a favorable determination of TLC compared with traditional plethysmography. The technique has general applicability across varying CT data acquisition protocols, lung diseases, and patient characteristics. TLCCT may substitute for TLCpleth in pulmonary function interpretation and may be preferable for some patients in whom plethysmography is difficult to perform, such as transplant subjects with severe pulmonary fibrosis.
Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C
Pottel, Hans , Delanaye, Pierre , Schäeffner, Elke , Dubourg, Laurence , Melsom, Toralf , Lamb, Edmund J. , Glassock, Richard J. , Souza, V. de , Selistre, Luciano da Silva , Goffin, Karolien , Pauwels, Steven , Mariat, Christophe , Flamant, Martin , Ebert, Natalie , Turner, Stephen T. , Eriksen, Björn O. , Rule, Andrew D. , Delanaye, Pierre , Schaeffner, Elke , Selistre, Luciano , Ebert, Natalie

Mayo Clinic

Nephrology Dialysis Transplantation | November 16, 2016 | Volume: 32 | Issue: 3 | Pages: 497-507

10.1093/ndt/gfw425 | PMID 28089986 Get It

Abstract Background. We recently published and validated the new serum creatinine (Scr)-based full-age-spectrum equation (FAScrea) for estimating the glomerular filtration rate (GFR) for healthy and kidney–diseased subjects of all ages. The equation was based on the concept of normalized Scr and shows equivalent to superior prediction performance to the currently recommended equations for children, adolescents, adults and older adults. Methods. Based on an evaluation of the serum cystatin C (ScysC) distribution, we defined normalization constants for ScysC (QcysC = 0.82 mg/L for ages &lt;70 years and QcysC = 0.95 mg/L for ages ≥70 years). By replacing Scr/Qcrea in the FAScrea equation with ScysC/QcysC, or with the average of both normalized biomarkers, we obtained new ScysC-based (FAScysC) and combined Scr-/ScysC-based FAS equations (FAScombi). To validate the new FAScysC and FAScombi we collected data on measured GFR, Scr, ScysC, age, gender, height and weight from 11 different cohorts including n = 6132 unique white subjects (368 children, aged ≤18 years, 4295 adults and 1469 older adults, aged ≥70 years). Results. In children and adolescents, the new FAScysC equation showed significantly better performance [percentage of patients within 30% of mGFR (P30) = 86.1%] than the Caucasian Asian Paediatric Adult Cohort equation (P30 = 76.6%; P &lt; 0.0001), or the ScysC-based Schwartz equation (P30 = 68.8%; P &lt; 0.0001) and the FAScombi equation outperformed all equations with P30 = 92.1% (P &lt; 0.0001). In adults, the FAScysC equation (P30 = 82.6%) performed equally as well as the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPIcysC) (P30 = 80.4%) and the FAScombi equation (P30 = 89.9%) was also equal to the combined CKD-EPI equation (P30 = 88.2%). In older adults, FAScysC was superior (P30 = 88.2%) to CKD-EPIcysC (P30 = 84.4%; P &lt; 0.0001) and the FAScombi equation (P30 = 91.2%) showed significantly higher performance than the combined CKD-EPI equation (P30 = 85.6%) (P &lt; 0.0001). Conclusion. The FAS equation is not only applicable to all ages, but also for all recommended renal biomarkers and their combinations.
A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands
Qin, Tai, Barron, Lindsey , Xia, Lu , Villarreal, Maria M., Zwaagstra, John C. , Collins, Cathy, Zwieb, Christian, Kodali, Ravindra, Hinck, Cynthia S. , Reddick, Robert L., O'Connor‐McCourt, Maureen D., Sun, Lu‐Zhe , Huang, Haojie , Yang, Junhua , Kim, Sun Kyung , Shu, Chang , Hinck, Andrew P.

Mayo Clinic

Oncotarget | November 15, 2016 | Volume: 7 | Issue: 52 | Pages: 86087-86102

10.18632/oncotarget.13343 | PMID 27863384 Get It

BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yokoyama, Yuhki , Zhu, Hengrui , Lee, Jeong Heon, Kossenkov, Andrew V. , Wu, Sherry Y. , Wickramasinghe, Jayamanna, Yin, Xiangfan, Palozola, Katherine C. , Showe, Louise C. , Zaret, Kenneth S. , Liu, Qin , Speicher, David W. , Conejo-García, José R. , Bradner, James E. , Zhang, Zhiguo , Ördög, Tamás , Bitler, Benjamin G. , Lee, Jeong‐Heon , Gardini, Alessandro , Sood, Anil K. , Zhang, Rugang , Zhang, Zhiguo , Lee, Jeong-Heon

Mayo Clinic

Cancer Research | November 1, 2016 | Volume: 76 | Issue: 21 | Pages: 6320-6330

10.1158/0008-5472.can-16-0854 | PMID 27803105 Get It

Abstract The emergence of tumor cells with certain stem-like characteristics, such as high aldehyde dehydrogenase (ALDH) activity due to ALDH1A1 expression, contributes to chemotherapy resistance and tumor relapse. However, clinically applicable inhibitors of ALDH activity have not been reported. There is evidence to suggest that epigenetic regulation of stem-related genes contributes to chemotherapy efficacy. Here, we show that bromodomain and extraterminal (BET) inhibitors suppress ALDH activity by abrogating BRD4-mediated ALDH1A1 expression through a super-enhancer element and its associated enhancer RNA. The clinically applicable small-molecule BET inhibitor JQ1 suppressed the outgrowth of cisplatin-treated ovarian cancer cells both in vitro and in vivo. Combination of JQ1 and cisplatin improved the survival of ovarian cancer–bearing mice in an orthotopic model. These phenotypes correlate with inhibition of ALDH1A1 expression through a super-enhancer element and other stem-related genes in promoter regions bound by BRD4. Thus, targeting the BET protein BRD4 using clinically applicable small-molecule inhibitors, such as JQ1, is a promising strategy for targeting ALDH activity in epithelial ovarian cancer. Cancer Res; 76(21); 6320–30. ©2016 AACR.
Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer
Win, Aung Ko , Jenkins, Mark A. , Antoniou, Antonis C. , Buchanan, Daniel D. , Rosty, Christophe , Ahnen, Dennis J. , Thibodeau, Stephen N. , Gallinger, Steven , Haile, Robert W., Zheng, Yingye , Lindor, Noralane M. , MacInnis, Robert J. , Haile, Robert W. , Dowty, James G. , Lee, Andrew , Giles, Graham G. , Clendenning, Mark , Casey, Graham , Marchand, Loı̈c Le , Potter, John D. , Zheng, Yingye , Newcomb, Polly A. , Hopper, John L. , Buchanan, Daniel D , Win, Aung K , Jenkins, Mark A , Haile, Robert W , Maclnnis, Robert , Rosty, Christophe

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 31, 2016 | Volume: 26 | Issue: 3 | Pages: 404-412

10.1158/1055-9965.epi-16-0693 | PMID 27799157 Get It

Abstract Background: Although high-risk mutations in identified major susceptibility genes (DNA mismatch repair genes and MUTYH) account for some familial aggregation of colorectal cancer, their population prevalence and the causes of the remaining familial aggregation are not known. Methods: We studied the families of 5,744 colorectal cancer cases (probands) recruited from population cancer registries in the United States, Canada, and Australia and screened probands for mutations in mismatch repair genes and MUTYH. We conducted modified segregation analyses using the cancer history of first-degree relatives, conditional on the proband's age at diagnosis. We estimated the prevalence of mutations in the identified genes, the prevalence of HR for unidentified major gene mutations, and the variance of the residual polygenic component. Results: We estimated that 1 in 279 of the population carry mutations in mismatch repair genes (MLH1 = 1 in 1,946, MSH2 = 1 in 2,841, MSH6 = 1 in 758, PMS2 = 1 in 714), 1 in 45 carry mutations in MUTYH, and 1 in 504 carry mutations associated with an average 31-fold increased risk of colorectal cancer in unidentified major genes. The estimated polygenic variance was reduced by 30% to 50% after allowing for unidentified major genes and decreased from 3.3 for age &lt;40 years to 0.5 for age ≥70 years (equivalent to sibling relative risks of 5.1 to 1.3, respectively). Conclusions: Unidentified major genes might explain one third to one half of the missing heritability of colorectal cancer. Impact: Our findings could aid gene discovery and development of better colorectal cancer risk prediction models. Cancer Epidemiol Biomarkers Prev; 26(3); 404–12. ©2016 AACR.
A comparison of tissue-based and recombinant protein–based assays for detecting PCA-Tr/DNER-IgG
Alfugham, Nora, Roforth, Matthew M., Komorowski, Lars , Ott, Anthonina, Meyer, Wolfgang , Probst, Christian , Lennon, Vanda A. , Pittock, Sean J. , McKeon, Andrew , Roforth, Matthew, Pittock, S J , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | October 29, 2016 | Volume: 3 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000000294 | PMID 27844036 Get It

Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality
Eisfeld, Ann‐Kathrin , Kohlschmidt, Jessica, Mrózek, Krzysztof , Volinia, Stefano , Blachly, James S. , Oakes, Christopher C. , Kroll, Karl, Carroll, Andrew J. , Stone, Richard M. , Byrd, John C. , Chapelle, Albert de la , Bloomfield, Clara D. , Byrd, John C. , Nicolet, Deedra , Orwick, Shelley J. , Blachly, James , Byrd, John C

Mayo Clinic

Cancer Research | October 26, 2016 | Volume: 77 | Issue: 1 | Pages: 207-218

10.1158/0008-5472.can-16-1386 | PMID 27784745 Get It

Abstract Monosomy of chromosome 7 is the most frequent autosomal monosomy in acute myeloid leukemia (AML), where it associates with poor clinical outcomes. However, molecular features associated with this sole monosomy subtype (-7 AML), which may give insights into the basis for its poor prognosis, have not been characterized. In this study, we analyzed 36 cases of -7 AML for mutations in 81 leukemia/cancer-associated genes using a customized targeted next-generation sequencing panel (Miseq). Global gene and miRNA expression profiles were also determined using paired RNA and small RNA sequencing data. Notably, gene mutations were detected in all the major AML-associated functional groups, which include activated signaling, chromatin remodeling, cohesin complex, methylation, NPM1, spliceosome, transcription factors, and tumor suppressors. Gene mutations in the chromatin remodeling groups were relatively more frequent in patients &lt;60 years of age, who also had less mutations in the methylation and spliceosome groups compared with patients ≥60 years of age. Novel recurrent mutational events in AML were identified in the SMARCA2 gene. In patients ≥60 years of age, the presence of spliceosome mutations associated with a lower complete remission rate (P = 0.03). RNA sequencing revealed distinct gene and miRNA expression patterns between the sole -7 and non -7 AML cases, with reduced expression, as expected, of many genes and miRNAs mapped to chromosome 7, and overexpression of ID1, MECOM, and PTPRM, among others. Overall, our findings illuminate a number of molecular features of the underlying aggressive pathobiology in -7 AML patients. Cancer Res; 77(1); 207–18. ©2016 AACR.
Progression of Interstitial Fibrosis during the First Year after Deceased Donor Kidney Transplantation among Patients with and without Delayed Graft Function
Heilman, Raymond L. , Qaqish, Ibrahim , Khamash, Hasan , Singer, Andrew L., Reddy, Kunam S. , Smith, Maxwell L. , Smith, Byron H. , Kaplan, Bruce

Mayo Clinic

Clinical Journal of the American Society of Nephrology | October 24, 2016 | Volume: 11 | Issue: 12 | Pages: 2225-2232

10.2215/cjn.05060516 | PMID 27797897 Get It

Background and objectives Delayed graft function is a form of AKI resulting from ischemia-reperfusion injury. Our aim was to study the effect of delayed graft function on the progression of interstitial fibrosis after deceased donor kidney transplantation. Design, setting, participants, & measurements Our study is a retrospective study of all patients transplanted at our center between July of 2003 and September of 2014 using a kidney from a deceased donor. The primary outcome was the progression of interstitial fibrosis on serial protocol biopsies done during the first year post-transplant. We analyzed the distribution of the change in the Banff interstitial fibrosis (ci) score between the delayed graft function and nondelayed graft function groups for all of the paired biopsies done at time 0 and 12 months post-transplant ( Δ fibrosis). We also performed a linear mixed model analyzing the difference in the slopes for the progression of mean Banff ci score for all of the biopsies done at time 0 and 1, 4, and 12 months post-transplant. Results There were 343 (36.7%) in the delayed graft function group and 591 in the control group. The biopsy rates for the delayed graft function and nondelayed graft function groups at time 0 were 65.3% ( n =224) and 67.0% ( n =396), respectively, and at 12 months, they were 64.4% ( n =221) and 68.4% ( n =404), respectively. Paired biopsies were available for 155 in the delayed graft function group and 283 in the control group. In a risk-adjusted model, Banff ci score >0 on the time 0 biopsy had a higher odds of delayed graft function (odds ratio, 1.70; 95% confidence interval, 1.03 to 2.82). The distribution of the Δ fibrosis between 0 and 12 months was similar in delayed graft function and control groups ( P =0.91). The slopes representing the progression of fibrosis were also similar between the groups ( P =0.66). Conclusions Donor-derived fibrosis may increase the odds of delayed graft function; however, delayed graft function does not seem to increase the progression of fibrosis during the first year after transplantation.
Transapical versus transfemoral approach and risk of acute kidney injury following transcatheter aortic valve replacement: a propensity-adjusted analysis
Cheungpasitporn, Wisit , Srivali, Narat , Harrison, Andrew M. , Kittanamongkolchai, Wonngarm , Greason, Kevin L. , Thongprayoon, Charat , Kashani, Kianoush , Harrison, Andrew Marc , Cheungpasitporn, Wisit , Srivali, Narat

Mayo Clinic

Renal Failure | October 21, 2016 | Volume: 39 | Issue: 1 | Pages: 13-18

10.1080/0886022x.2016.1244072 | PMID 27767371 Get It